Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 187Global Cancer Incidence and ScreeningCOVID-19 and healthcare impactsColorectal Cancer Screening and Detection

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

The impact of episodic screening interruption: COVID-19 and population-based cancer screening in Canada

Open access
Yong, Jean HE, Mainprize, James G, Yaffe, Martin J, Ruan, Yibing, Poirier, Abbey E, Coldman, Andrew, Nadeau, Claude, Iragorri, Nicolas, Hilsden, Robert J, Brenner, Darren R·2021·Journal of Medical Screening
DOI 10.1177/0969141320974711PMC PMC7691762
Open this paper in CoChat — free account

Abstract

Background: Population-based cancer screening can reduce cancer burden but was interrupted temporarily due to the COVID-19 pandemic. We estimated the long-term clinical impact of breast and colorectal cancer screening interruptions in Canada using a validated mathematical model. Methods: We used the OncoSim breast and colorectal cancers microsimulation models to explore scenarios of primary screening stops for 3, 6, and 12 months followed by 6–24-month transition periods of reduced screening volumes. For breast cancer, we estimated changes in cancer incidence over time, additional advanced-stage cases diagnosed, and excess cancer deaths in 2020–2029. For colorectal cancer, we estimated changes in cancer incidence over time, undiagnosed advanced adenomas and colorectal cancers in 2020, and lifetime excess cancer incidence and deaths. Results: Our simulations projected a surge of cancer cases when screening resumes. For breast cancer screening, a three-month interruption could increase cases diagnosed at advanced stages (310 more) and cancer deaths (110 more) in 2020–2029. A six-month interruption could lead to 670 extra advanced cancers and 250 additional cancer deaths. For colorectal cancers, a six-month suspension of primary screening could increase cancer incidence by 2200 cases with 960 more cancer deaths over the lifetime. Longer interruptions, and reduced volumes when screening resumes, would further increase excess cancer deaths. Conclusions: Interruptions in cancer screening will lead to additional cancer deaths, additional advanced cancers diagnosed, and a surge in demand for downstream resources when screening resumes. An effective strategy is needed to minimize potential harm to people who missed their screening.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0969141320974711

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. (a) Projected number of incident cases in Canada (*invasive cancer and DCIS combined) in 2018–2026 for the no interruption scenario, 3-, 6-, and 12-month interruption scenarios. (b) Projected cumulative excess breast cancer deaths (95% confidence intervals) for 3-, 6-, and 12-month interruptions. (c) Projected cumulative excess breast cancer deaths for 6-month interruption followed by 6-, 12-, and 24-months of 50% reduced capacity transition periods. (d) Projected cumulative excess breast cancer deaths for 12-month interruption followed by 12- and 24-months of 50% reduced capacity transition periods.
Figure 1. (a) Projected number of incident cases in Canada (*invasive cancer and DCIS combined) in 2018–2026 for the no interruption scenario, 3-, 6-, and 12-month interruption scenarios. (b) Projected cumulative excess breast cancer deaths (95% confidence intervals) for 3-, 6-, and 12-month interruptions. (c) Projected cumulative excess breast cancer deaths for 6-month interruption followed by 6-, 12-, and 24-months of 50% reduced capacity transition periods. (d) Projected cumulative excess breast cancer deaths for 12-month interruption followed by 12- and 24-months of 50% reduced capacity transition periods.CC BY · PubMed Central
Figure 2. (a) Projected number of incident colorectal cancer cases in Canada in 2018–2026 for the no interruption scenario, 3-, 6-, and 12-month interruption scenarios. (b) Projected cumulative excess colorectal cancer deaths (95% confidence intervals) for 3-, 6-, and 12-month interruptions. (c) Projected cumulative excess colorectal cancer deaths for 6-month interruption followed by 6-, 12-, and 18-months of 50% reduced capacity transition periods. (d) Projected cumulative excess colorectal cancer deaths for 12-month interruption followed by 12- and 24-months of 50% reduced capacity transition periods.
Figure 2. (a) Projected number of incident colorectal cancer cases in Canada in 2018–2026 for the no interruption scenario, 3-, 6-, and 12-month interruption scenarios. (b) Projected cumulative excess colorectal cancer deaths (95% confidence intervals) for 3-, 6-, and 12-month interruptions. (c) Projected cumulative excess colorectal cancer deaths for 6-month interruption followed by 6-, 12-, and 18-months of 50% reduced capacity transition periods. (d) Projected cumulative excess colorectal cancer deaths for 12-month interruption followed by 12- and 24-months of 50% reduced capacity transition periods.CC BY · PubMed Central
Figure 3. (a) Impact of interruption to mammography on additional breast cancers diagnosed between 2020 and 2029 at a later stage resulting from a 3-, 6-, and 12-month service interruption in Canada. (b) Lifetime impact of colorectal cancer screening interruptions on additional colorectal cancers, stratified by cancer stages, resulting from a 3-, 6-, and 12-month interruptions.
Figure 3. (a) Impact of interruption to mammography on additional breast cancers diagnosed between 2020 and 2029 at a later stage resulting from a 3-, 6-, and 12-month service interruption in Canada. (b) Lifetime impact of colorectal cancer screening interruptions on additional colorectal cancers, stratified by cancer stages, resulting from a 3-, 6-, and 12-month interruptions.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 5

  1. Canadian Partnership Against Cancer, 2019, 2019–2029 Canadian strategy for cancer control
  2. Canadian Partnership Against Cancer, 2018, Colorectal cancer screening in Canada: Environmental scan
  3. Canadian Partnership Against Cancer, 2018, Breast cancer screening in Canada: environmental scan
  4. Cancer Care Ontario., 2016, Ontario cancer screening performance report 2016
  5. Blumen H, 2016, Am Health Drug Benefits, 9, 23

Cited by

Items 101–187 of 187

Related

See all

Metadata

Authors
Yong, J. H., Mainprize, J. G., Yaffe, M. J., Ruan, Y., Poirier, A. E., Coldman, A., Nadeau, C., Iragorri, N., Hilsden, R. J., & Brenner, D. R.
Affiliations
  • Independent Consultant, Toronto, Canada
  • Sunnybrook Hospital (CA)
  • University of Toronto (CA)
  • Alberta Health Services (CA)
  • British Columbia Cancer Research, Vancouver, Canada
  • Statistics Canada (CA)
Corresponding author
Yaffe, Martin J
ORCID
Venue
Journal of Medical Screening
Publisher
SAGE Publications
Published
2020-11-26
Volume
28
Issue
2
Pages
100-107
ISSN
  • 0969-1413 (ISSN-L)
  • 1475-5793
DOI
10.1177/0969141320974711
PMC
PMC7691762
OpenAlex
W3108766839
Cited by
187
References
12
Citations by year
2026: 6 · 2025: 13 · 2024: 29 · 2023: 45 · 2022: 63 · 2021: 30 · 2020: 1
FWCI
12.54
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Medical Screening (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
  • Health Sciences › Medicine › Oncology › COVID-19 and healthcare impacts
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
Keywords
COVID-19 pandemic, breast cancer screening, colorectal cancer screening, mass screening, advanced cancer, cancer incidence, cancer mortality, missed screening, Canada
MeSH terms
COVID-19, Breast Neoplasms, Canada, Female, Humans, Male, Colorectal Neoplasms, Incidence, Early Detection of Cancer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.